Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Lateral Crow's Feet: Double-Blind, Placebo-Controlled, Dose-Ranging Study
Article first published online: 20 JUL 2009
© 2009 by the American Society for Dermatologic Surgery, Inc.
Volume 35, Issue 10, pages 1478–1486, October 2009
How to Cite
ASCHER, B., RZANY, B. J. and GROVER, R. (2009), Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Lateral Crow's Feet: Double-Blind, Placebo-Controlled, Dose-Ranging Study. Dermatologic Surgery, 35: 1478–1486. doi: 10.1111/j.1524-4725.2009.01261.x
- Issue published online: 1 OCT 2009
- Article first published online: 20 JUL 2009
BACKGROUND Botulinum toxin type A (BoNT-A) is frequently used to treat crow's feet; the optimal dose for each toxin preparation should be established.
OBJECTIVE To compare the efficacy and safety of three doses of BoNT-A with placebo to treat crow's feet.
METHODS Subjects with moderate to severe crow's feet at maximum smile (mild to severe at rest) were randomized to a single bilateral BoNT-A treatment (15, 30, or 45 U) or placebo. Outcome measures included evaluation of crow's feet by an independent panel from blinded photographs at maximum smile, investigator assessment, and patient satisfaction.
RESULTS Independent panel assessments (Week 4) showed that all BoNT-A doses resulted in significant improvements in crow's feet severity at maximum smile (p<.001); a clear dose–response effect was seen. Improvement over placebo was seen in the 30-U and 45-U groups to Week 12. Investigator assessment showed significant improvement for all doses for 12 weeks at maximum smile and rest (p≤.01). Patient satisfaction was significantly greater for all doses than for placebo for 16 weeks (all p<.05). All doses were well tolerated.
CONCLUSION BoNT-A (15, 30, or 45 U) is an effective and safe treatment for mild to severe crow's feet.